Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion

• US 7,493,171 B1
• Filed: 05/27/2005
• Issued: 02/17/2009
• Est. Priority Date: 11/21/2000
• Status: Active Grant

• Current Assignee: Boston Scientific Neuromodulation Corporation (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Neuromodulation Corporation (Boston Scientific Corporation)
• Inventors: Jaax, Kristen N, Makous, James C, Carbunaru, Rafael, Whitehurst, Todd K
• Primary Examiner(s): Manuel; George
• Assistant Examiner(s): Flory; Christopher A
• Application Number:
  US11/140,152
• Time in Patent Office: 1,362 Days
• Field of Search: 607/45, 607/58
• US Class Current: 607/58
• CPC Class Codes: A61M 2005/1726 the body parameters being measured at, or proximate to, the infusion site
• CPC Class Codes: A61M 2205/054 with electrotherapy
• CPC Class Codes: A61M 2205/3523 using telemetric means
• CPC Class Codes: A61M 2205/50 with microprocessors or computers
• CPC Class Codes: A61M 2210/06 Head
• CPC Class Codes: A61M 2210/0693 Brain, cerebrum
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61N 1/00 Electrotherapy; Circuits therefor A61N2/00 takes precedence; irradiation apparatus A61N5/00
• CPC Class Codes: A61N 1/0531 Brain cortex electrodes
• CPC Class Codes: A61N 1/0534 Electrodes for deep brain stimulation
• CPC Class Codes: A61N 1/36082 Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
• CPC Class Codes: A61N 1/36089 Addiction or withdrawal from substance abuse such as alcohol or drugs

Abstract

Systems and methods for introducing one or more stimulating drugs and/or applying electrical stimulation to the brain to at least treat or prevent obesity and/or other eating disorders, as well as drug, nicotine and alcohol addiction, uses at least one system control unit (SCU) producing electrical pulses delivered via electrodes implanted in the brain and/or producing drug infusion pulses, wherein the stimulating drug(s) are delivered to targeted areas in the brain.

Claims

1. A method of treating a patient with an alcohol addiction, comprising:

implanting one or more system control units in the patient, wherein one or more of the system control units are connected to and control one or more electrodes and/or drug delivery catheters that are implanted in the brain of the patient; and

delivering a stimulus configured to treat the alcohol addiction with one or more of the system control units via the one or more electrodes and/or drug delivery catheters to at least one of an anterior insula and a dorsal putamen.

2. The method of claim 1, wherein the one or more system control units are configured to receive power and/or data by RF transmission.

3. The method of claim 1, wherein the one or more system control units are percutaneous and connected to one or more electrodes by a percutaneous lead.

4. The method of claim 1, wherein the one or more system control units are configured to receive power and/or data by direct electrical connection.

5. The method of claim 1, wherein the one or more system control units comprises at least one microstimulator.

6. The method of claim 1, wherein the stimulus is configured to prevent accommodation.

7. The method of claim 1, further comprising customizing the stimulus to the patient.

8. The method of claim 1, wherein the stimulus comprises electrical stimulation delivered via the one or more electrodes.

9. The method of claim 1, wherein the stimulus comprises one or more drugs delivered via the drug delivery catheters.

10. The method of claim 1, further comprising sensing at least one condition related to the alcohol addiction and adjusting the stimulus according to the sensed condition.

11. A method of treating a patient with an eating disorder, comprising:

electronically sensing at least one condition indicating a need for stimulus to one or more brain areas in the patient that are related to said eating disorder by a sensor that sends an electronic signal to at least one system control unit, thereby activating the at least one system control unit; and

delivering a stimulus via one or more electrodes and/or drug delivery catheters that are implanted in the brain of the patient and that are controlled by the activated at least one system control unit, wherein the stimulus is delivered to the one or more areas of the brain related to said eating disorder;

wherein the one or more areas of the brain related to said eating disorder comprise at least one or more of a nucleus of the solitary tract, an insula cortex, a medulla, and a parahippocampus.

12. The method of claim 11, wherein the sensed condition comprises at least one of a regional cerebral blood flow (rCBF), an impedance, a pH level, an electrical activity of the brain, a nerve activity, a muscle activity, a neurotransmitter level, a neurotransmitter breakdown product level, a hormone level, a ketone level, a glucose level, an electrolyte level, an enzyme level, a cytokine level, a medication level, a drug level, and a level of a bloodborne substance.

13. The method of claim 11, wherein the stimulus comprises a compound that increases excitement of at least one area of the brain that exhibits chronic decreased activity.

14. The method of claim 11, wherein the stimulus comprises at least one or more of an excitatory neurotransmitter agonist, a medication that increases levels of at least one excitatory neurotransmitter, an excitatory hormone agonist, an inhibitory neurotransmitter antagonist, an inhibitory hormone antagonist, corticotropin releasing factor, a corticotropin releasing factor agonist, bombesin, a bombesin agonist, glucagon-like peptide 1, a glucagon-like peptide 1 agonist, serotonin, a serotonin agonist, leptin, a leptin agonist, a ghrelin antagonist, an AGRP antagonist, an MC4-R agonist, an MC3-R agonist, an orexin-A antagonist, an orexin-B antagonist, an OX1R antagonist, an OX2R antagonist, cholecystokinin, a cholecystokinin agonist, dopamine, dynorphin, melanin-concentrating hormone, melanocyte-stimulating hormone, growth hormone-releasing hormone (GHRH), endocannobinoids, beta-endorphin, and galanin.

15. The method of claim 11, wherein the stimulus comprises a compound that decreases excitement of at least one area of the brain that exhibits chronic increased activity.